Placebo for migraine disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 5 Feb 2020: Trial registered, NCT04252742
  2. 15 Sep 2020: Trial started, NCT04252742

The trials

NCT04218539: Repeat Dosing of Psilocybin in Migraine Headache

State
Completed
Phase
Phase 1
People
18 taking part
Started
10 Aug 2021
Primary completion
5 Nov 2023
Arms
Placebo/Placebo
Results
None posted
  1. 6 Jan 2020: Trial registered
  2. 10 Aug 2021: Trial started
  3. 5 Nov 2023: Trial completed

NCT04252742: Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

State
Completed
Phase
Phase 4
People
512 taking part
Started
15 Sep 2020
Primary completion
26 Oct 2023
Arms
Placebo
Results
Posted on the registry
  1. 5 Feb 2020: Trial registered
  2. 15 Sep 2020: Trial started
  3. 26 Oct 2023: Trial completed
  4. 30 Aug 2024: Trial results posted

NCT07304518: Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults

State
Under way
Phase
Phase 2
People
456 planned
Started
26 Jan 2026
Primary completion
Sep 2026
Arms
Placebo
Results
None posted
  1. 26 Dec 2025: Trial registered
  2. 26 Jan 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.